Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

Dow Jones10-30

By Kosaku Narioka

Takeda Pharmaceutical cut its annual earnings forecasts as impairment charges for discontinued drug research pushed the company into the red in the latest quarter.

The Japanese drugmaker said Thursday that it swung to a net loss of 11.8 billion yen, equivalent to $77.3 million, for the three months ended September, from net profit of Y92.0 billion in the year-earlier period. The result was worse than the Y65.2 billion net profit estimate in a poll of analysts by data provider Visible Alpha.

Takeda recorded impairment charges of about Y58 billion in its second quarter related to the cell-therapy research it discontinued as part of a strategic portfolio review.

For the fiscal year ending March, it projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. The company previously expected revenue of Y4.530 trillion and net profit of Y228.00 billion.

Second-quarter revenue dropped 5.4% to Y1.113 trillion. Sales of plasma-derived products declined 2.9% to Y256.6 billion, while sales of ulcerative colitis drug Entyvio rose 3.3% to Y246.7 billion.

Write to Kosaku Narioka at kosaku.narioka@wsj.com

(END) Dow Jones Newswires

October 30, 2025 05:24 ET (09:24 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579846118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579846118","market":"nz","top_or_hot":-1,"title":"Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kosaku Narioka \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Takeda Pharmaceutical cut its annual earnings forecasts as impairment charges for discontinued drug research pushed the company into the red in the latest quarter. \n</p>\n<p>\n  The Japanese drugmaker said Thursday that it swung to a net loss of 11.8 billion yen, equivalent to $77.3 million, for the three months ended September, from net profit of Y92.0 billion in the year-earlier period. The result was worse than the Y65.2 billion net profit estimate in a poll of analysts by data provider Visible Alpha. \n</p>\n<p>\n  Takeda recorded impairment charges of about Y58 billion in its second quarter related to the cell-therapy research it discontinued as part of a strategic portfolio review. \n</p>\n<p>\n  For the fiscal year ending March, it projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. The company previously expected revenue of Y4.530 trillion and net profit of Y228.00 billion. \n</p>\n<p>\n  Second-quarter revenue dropped 5.4% to Y1.113 trillion. Sales of plasma-derived products declined 2.9% to Y256.6 billion, while sales of ulcerative colitis drug Entyvio rose 3.3% to Y246.7 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 05:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-30 17:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kosaku Narioka \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Takeda Pharmaceutical cut its annual earnings forecasts as impairment charges for discontinued drug research pushed the company into the red in the latest quarter. \n</p>\n<p>\n  The Japanese drugmaker said Thursday that it swung to a net loss of 11.8 billion yen, equivalent to $77.3 million, for the three months ended September, from net profit of Y92.0 billion in the year-earlier period. The result was worse than the Y65.2 billion net profit estimate in a poll of analysts by data provider Visible Alpha. \n</p>\n<p>\n  Takeda recorded impairment charges of about Y58 billion in its second quarter related to the cell-therapy research it discontinued as part of a strategic portfolio review. \n</p>\n<p>\n  For the fiscal year ending March, it projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. The company previously expected revenue of Y4.530 trillion and net profit of Y228.00 billion. \n</p>\n<p>\n  Second-quarter revenue dropped 5.4% to Y1.113 trillion. Sales of plasma-derived products declined 2.9% to Y256.6 billion, while sales of ulcerative colitis drug Entyvio rose 3.3% to Y246.7 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 05:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579846118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579846118","pubTimestamp":1761816240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Takeda Pharmaceutical cut its annual earnings forecasts as impairment charges for discontinued drug research pushed the company into the red in the latest quarter.The Japanese drugmaker said Thursday that it swung to a net loss of 11.8 billion yen, equivalent to $77.3 million, for the three months ended September, from net profit of Y92.0 billion in the year-earlier period. The result was worse than the Y65.2 billion net profit estimate in a poll of analysts by data provider Visible Alpha.Takeda recorded impairment charges of about Y58 billion in its second quarter related to the cell-therapy research it discontinued as part of a strategic portfolio review.For the fiscal year ending March, it projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. The company previously expected revenue of Y4.530 trillion and net profit of Y228.00 billion.Second-quarter revenue dropped 5.4% to Y1.113 trillion. Sales of plasma-derived products declined 2.9","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"武田因减值费用而陷入亏损，下调指引——更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"By Kosaku Narioka \n\n\n \n\n\n  Takeda Pharmaceutical cut its annual earnings forecasts as impairment charges for discontinued drug research pushed the company into the red in the latest quarter. \n\n\n  The Japanese drugmaker said Thursday that it swung to a net loss of 11.8 billion yen, equivalent to $77.3 million, for the three months ended September, from net profit of Y92.0 billion in the year-earlier period. The result was worse than the Y65.2 billion net profit estimate in a poll of analysts by data provider Visible Alpha. \n\n\n  Takeda recorded impairment charges of about Y58 billion in its second quarter related to the cell-therapy research it discontinued as part of a strategic portfolio review. \n\n\n  For the fiscal year ending March, it projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. The company previously expected revenue of Y4.530 trillion and net profit of Y228.00 billion. \n\n\n  Second-quarter revenue dropped 5.4% to Y1.113 trillion. Sales of plasma-derived products declined 2.9% to Y256.6 billion, while sales of ulcerative colitis drug Entyvio rose 3.3% to Y246.7 billion. \n\n\n \n\n\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 05:24 ET (09:24 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579846118","isCrawlerRequest":true}